In a report released yesterday, Kelly Shi from Jefferies maintained a Buy rating on Immatics (IMTX – Research Report), with a price target of $20.00. The company’s shares closed yesterday at $9.84.
Shi covers the Healthcare sector, focusing on stocks such as CTI BioPharma, ImmunityBio, and TCR2 Therapeutics. According to TipRanks, Shi has an average return of -13.9% and a 36.11% success rate on recommended stocks.
Immatics has an analyst consensus of Strong Buy, with a price target consensus of $18.25, implying an 85.56% upside from current levels. In a report released on May 3, Mizuho Securities also reiterated a Buy rating on the stock with a $12.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
IMTX market cap is currently $754.1M and has a P/E ratio of 20.35.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Immatics NV is engaged in discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company’s pipeline consists of two lead product classes, engineered Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics (TCER). Each therapeutic modality has distinct attributes to produce the desired therapeutic effect for patients at different disease stages and with different types of tumors focusing on particularly hard-to-treat solid cancers.
Read More on IMTX:
- Immatics Announces First Quarter 2023 Financial Results and Business Update
- Immatics N.V. (IMTX) Q1 Earnings Cheat Sheet
- Immatics Soars after Positive Clinical Update
- Immatics reports interim clinical data from ongoing Phase 1b Cohort A
- Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME
